Finance

Lists
Outlook: 53.3% bullish·6.7% bearish
Go to analysis
DTIL:NASDAQ
Precision BioSciences Inc
$9.50
-1.86%
(-0.18) 1D
$9.50
0.00% (0.00)
After hours
Closed: Nov 10, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DTIL...
Open
$9.60
High
$10.02
Low
$9.22
Mkt. cap
362.22M
Avg. vol.
362.55K
Volume
352.81K
52-wk high
$10.81
52-wk low
$3.53
EPS
-$1.23
Beta
1.35
Shares outstanding
27.94M
No. of employees
69
Open
$9.60
High
$10.02
Low
$9.22
Mkt. cap
362.22M
Avg. vol.
362.55K
Volume
352.81K
52-wk high
$10.81
52-wk low
$3.53
EPS
-$1.23
Beta
1.35
Shares outstanding
27.94M
No. of employees
69
News stories
From web sources and news partners
Profile
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform. Wikipedia
About Precision BioSciences Inc
CEO-
Employees69
Founded2006
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteprecisionbiosciences.com
Analyst ratings
Based on 2 analysts giving stock ratings to DTIL in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for DTIL in the last 3 months.
Highest
Current $9.50
$60.00 (+531.58%)
Average
$40.00 (+321.05%)
Lowest
$20.00 (+110.53%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$60.00
+531.6%
11/10/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
$20.00
+110.5%
11/10/2026
Catherine Novack
JonesTrading
Buy
Reiterated
$30.00
+215.8%
08/07/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$19.00
+100%
05/28/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$19.00
+100%
03/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
34.20M
10.84M
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
14.46M
13.11M
12.39M
12.74M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.23M
6.80M
6.77M
7.68M
Operating expense
21.70M
19.91M
19.16M
20.43M
Total operating expenses
21.70M
19.91M
19.16M
20.43M
Operating income
12.51M
-9.08M
-19.16M
-20.43M
Other non operating income
12.11M
-7.11M
-13.89M
12.72M
EBT including unusual items
19.25M
-18.44M
-32.65M
-7.59M
EBT excluding unusual items
19.67M
-15.49M
-32.41M
-7.13M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
20.13M
-18.44M
-32.65M
-7.59M
Net profit margin
58.86%
-170.15%
-
-
Earnings per share
1.01
-0.75
-1.26
-0.28
Interest and investment income
773.00K
999.00K
943.00K
881.00K
Interest expense
-348.00K
-311.00K
-300.00K
-307.00K
Net interest expenses
425.00K
688.00K
643.00K
574.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
12.85M
-8.78M
-18.91M
-20.21M
Gain or loss from assets sale
-465.00K
-4.00K
-1.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps